BioStem Technologies (OTCMKTS:BSEM) Posts Quarterly Earnings Results, Beats Estimates By $0.31 EPS

BioStem Technologies (OTCMKTS:BSEM) announced its quarterly earnings results on Monday. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.31, Zacks reports.

BioStem Technologies Stock Down 0.2 %

Shares of OTCMKTS:BSEM traded down $0.02 on Monday, hitting $12.89. The company had a trading volume of 186,288 shares, compared to its average volume of 62,769. The firm’s 50-day simple moving average is $11.86 and its two-hundred day simple moving average is $13.72. The firm has a market capitalization of $215.30 million, a price-to-earnings ratio of 18.96 and a beta of 0.09. BioStem Technologies has a 1 year low of $6.77 and a 1 year high of $28.26.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.